Výsledky vyhledávání - "Deanna Hogue"

Abstract OT1-16-01: A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2 positive breast cancer

Autor: Hyo S Han, Mary Disis, Robert Wesolowski, Carla Fisher, Shipra Gandhi, Nancy Chan, William Gwin, Keerthi Gogineni, Rosemarie Mick, Christina Sierra Rodriguez, Deanna Hogue, Hien Liu, Ricardo Costa, Brian Czerniecki

Publikováno v: Cancer Research. 82:OT1-16

Background: HER2-positive breast cancer patients are commonly treated with neoadjuvant therapy including HER2-targeted therapy. Patients who have residual invasive disease have less favorable outcomes with an increased risk of recurrent disease than

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2bda760a0d3609c9c3a0503bfd6760dc
https://doi.org/10.1158/1538-7445.sabcs21-ot1-16-01

Zobrazit plný text záznamu

Abstract P5-11-05: The cardo-oncology concerns of combining tamoxifen and ribociclib based on the TEEL trial

Autor: Deanna Hogue, Hyo S. Han, Hatem Soliman, Roohi Ismail-Khan, Michael G. Fradley, Martine Extermann

Publikováno v: Cancer Research. 80:P5-11

Background: The TEEL Study was an open labeled, non-randomized; phase I dose escalation followed by a planned phase Ib dose expansion trial of Tamoxifen (Tam) with Ribociclib (Ribo) in adult patients with advanced ER+ (HER2 negative) breast cancer. R

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95e41eb3baf760c516ce80b3856b6d90
https://doi.org/10.1158/1538-7445.sabcs19-p5-11-05

Zobrazit plný text záznamu

A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer

Autor: Bethany L. Niell, Alec Chau, Angela Williams, Blaise Mooney, Nazanin Khakpour, Susan Hoover, Deanna Hogue, Hung Khong, Marilin Rosa, Ricardo Costa, Brian J. Czerniecki, Shannon Falcon, Marie C. Lee, Robert J. Weinfurtner, Hatem Soliman, Hyo S. Han, John V. Kiluk

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 27(4)

Purpose: Talimogene laherparepvec (TVEC) is an oncolytic herpes simplex 1 virus approved for treatment of melanoma. We hypothesized intratumoral TVEC may enhance response to neoadjuvant chemotherapy (NAC). This article reports the results of a trial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1bd7549f2af9b08a3c1302eb2a1031e
https://pubmed.ncbi.nlm.nih.gov/33219014

Zobrazit plný text záznamu

Abstract OT2-07-01: Phase 1/2 trial of the oncolytic virus, talimogene laherparpvec, in combination with neoadjuvant chemotherapy in stage II/III triple negative breast cancer

Autor: Roohi Ismail-Khan, C Lee, Hatem Soliman, HS Han, Brian J. Czerniecki, Hung T. Khong, Deanna Hogue, Bethany L. Niell

Publikováno v: Cancer Research. 78:OT2-07

Background: The host anti-tumor immune response plays an important role in determining natural history and therapy response for early stage breast cancer. Tumors with high levels of lymphocytic infiltration appear to have a superior prognosis and res

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::04e9d742c253598dd2a5e80452baca70
https://doi.org/10.1158/1538-7445.sabcs17-ot2-07-01

Zobrazit plný text záznamu

Abstract P4-22-23: Phase II trial of selinexor for metastatic triple negative breast cancer

Autor: Hatem Soliman, HS Han, Jae K. Lee, Roohi Ismail-Khan, Daniel C. Sullivan, Loretta Loftus, Martine Extermann, D Carney, Deanna Hogue

Publikováno v: Cancer Research. 77:P4-22

Background: XPO1 (also known as CRM1) is the exclusive nuclear exporter of multiple tumor suppressor proteins (TSP) including p53, p21, BRCA1/2, pRB, FOXO. XPO1 inhibition forces nuclear accumulation of TSPs, thus inducing apoptosis in cancer cells.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb7cebd4c9da5f82d81570503a9bd775
https://doi.org/10.1158/1538-7445.sabcs16-p4-22-23

Zobrazit plný text záznamu

Abstract OT1-01-06: A pilot study utilizing a HER2 directed dendritic cell vaccine during neoadjuvant therapy of HER2+ breast cancer

Autor: Hung Khong, Ricardo Costa, Brian J. Czerniecki, Axia Soyano Muller, Hatem Soliman, Nazanin Khakpour, Avan Armaghani, Marie C. Lee, Hyo S. Han, John V. Kiluk, Deanna Hogue

Publikováno v: Cancer Research. 80:OT1-01

Background: During the natural progression of early breast cancer, it has been demonstrated that the protective host immune response against HER2 is lost early on. Using a type 1 dendritic cell (DC1) vaccine loaded with HER2 peptides has been shown t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2f400635064746a0c7b8a730e3803ac6
https://doi.org/10.1158/1538-7445.sabcs19-ot1-01-06

Zobrazit plný text záznamu

A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer

Autor: Michael R. Shafique, Daniel C. Sullivan, David Boulware, Hyo S. Han, Roohi Ismail-Khan, Hatem Soliman, Martine Extermann, Deanna Hogue, Hung Khong, Dawn Goodridge

Publikováno v: The Oncologist

Lessons Learned Single-agent selinexor has limited activity in heavily pretreated patients with metastatic triple-negative breast cancer. Selinexor 60 mg by mouth twice weekly was generally well tolerated with a side-effect profile consistent with pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe9fa7f4414d61d1320b430f13b6548b
https://doi.org/10.1634/theoncologist.2019-0231

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání